Key result
Low-dose spironolactone reduced the composite of CCV death, aborted cardiac arrest, and sudden cardiac death compared to placebo (7.2% vs 18.0%; HR 0.42; 95% CI 0.26-0.78).
Why the study?
Does spironolactone reduce the composite of death from cardiocerebrovascular events, aborted cardiac arrest, and sudden cardiac death in non-heart failure dialysis patients with end-stage renal disease?
RCT (n=253)
placebo-controlled
randomly assigned
Yes
Does spironolactone reduce the composite of death from cardiocerebrovascular events, aborted cardiac arrest, and sudden cardiac death in non-heart failure dialysis patients with end-stage renal disease?
Hazard Ratio: 0.42 (95% CI 0.26–0.78)
Absolute Event Rate: 7.2% vs 18%
Low-dose spironolactone significantly reduces the risk of cardiocerebrovascular morbidity and mortality in non-heart failure dialysis patients.
No takes yet. Share an insight, caveat, or question.
Supports low-dose spironolactone for cardiocerebrovascular risk reduction in non-HF dialysis patients; extends MRA evidence beyond heart failure.
Lin et al. (2015) conducted an RCT in end-stage renal disease on chronic dialysis without heart failure (n=253). spironolactone vs. matching placebo was evaluated on composite of death from cardiocerebrovascular (CCV) events, aborted cardiac arrest, and sudden cardiac death (HR 0.42, 95% CI 0.26-0.78). Low-dose spironolactone reduced the composite of CCV death, aborted cardiac arrest, and sudden cardiac death compared to placebo (7.2% vs 18.0%; HR 0.42; 95% CI 0.26-0.78).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: